Esperion Therapeutics (ESPR) Tops Q4 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $20.57 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'